Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance

Substance Use and Misuse

Volumn 45, Issue 1-2, 2010, Pages 288-313

  Ponizovsky, Alexander M ^a   Margolis, Anatoly ^a   Heled, Ludmila ^a   Rosca, Paula ^a   Radomislensky, Irena ^a   Grinshpoon, Alexander ^a  

^a MINISTRY OF HEALTH   (Israel)

Author keywords

Ambulatory maintenance; Buprenorphine; Emotional distress; Heroin dependence; Quality of life; Self efficacy; Side effects; Social support

Indexed keywords

ADOLESCENT; ADULT; AMBULATORY CARE; BUPRENORPHINE; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SELF EFFICACY; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 73849089515     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826080902873010     Document Type: Article

References (78)

1. Ahmadi, J. (2003). Methadone versus buprenorphine maintenance for the treatment of heroindependent outpatients. Journal of Substance Abuse Treatment, 24:217-220. (Pubitemid 37297338)
2. Amato, L., Davoli, M. A., Perucci, C., Ferri, M., Faggiano, F. P., Mattick, R. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28: 321-329.
3. Bandura, A. (1994). Self-efficacy. In V. S. Ramachaudran (Ed.), Encyclopedia of human behavior (Vol. 4, pp. 71-81). New York: Academic Press.
4. Barnett, P. G., Rodgers, J. H., Bloch, D. A. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction, 96:683-690.
5. Ben-Ari, A., Gil, S. (2002). Traditional support systems: Are they sufficient in a culturally diverse academic environment? British Journal of Social Work, 32:629-638.
6. Bosscher, R. J., Smit, J. H. (1998). Confirmatory factor analysis of the General Self-Efficacy Scale. Behaviour Research and Therapy, 36:339-343.
7. Burleson, J. A., Kaminer, Y. (2005). Self-efficacy as a predictor of treatment outcome in adolescent substance use disorders. Addictive Behaviors, 30:1751-1764.
8. Caldiero, R. M., Parran, T. V., Jr., Adelman, C. L., Piche, B. (2006). Inpatient initiation of buprenorphine maintenance vs. detoxification: Can retention of opioid-dependent patients in outpatient counseling be improved? American Journal of Addiction, 15:1-7.
9. Carrieri, M. P., Amass, L., Lucas, G.M., Vlahov, D.,Wodak, A.,Woody, G. E. (2006). Buprenorphine use: The international experience. Clinical Infectious Diseases, 43(Suppl. 4):197-215.
10. Cheskin, L. J., Fudala, P. J., Johnson, R. E. (1994). A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence, 36:115-121.
11. Chutuape, M. A., Jasinski, D. R., Fingerhood, M. I., Stitzer, M. L. (2001). One-, three-, and sixmonth outcomes after brief inpatient opioid detoxification. American Journal of Drug and Alcohol Abuse, 27:19-44.
12. Clark, R. E. (2001). Family support and substance use outcomes for persons with mental illness and substance use disorders. Schizophrenia Bulletin, 27:93-101.
13. Clark, N., Lintzeris, N., Gijsbers, A., Whelan, G. (2003). LAAM maintenance versus methadone maintenance for heroin dependence. Cochrane Review, The Cochrane Library, Issue 3, Oxford, Software update.
14. Colameco, S., Armando, J., Trotz, C. (2005). Opiate dependence treatment with buprenorphine: One year's experience in a family practice residency setting. Journal of Addictive Disorders, 24:25-32.
15. Cozzolino, E., Guglielmino, L., Vigezzi, P., Marzorati, P., Silenzio, R., De Chiara, M., et al. (2006). Buprenorphine treatment: A three-year prospective study in opioid-addicted patients of a public out-patient addiction center in Milan. American Journal of Addiction, 15:246-251.
16. Duburcq, A., Charpak, Y., Blin, P., Madec, L.,(2000). Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice SUBUTEX). Review of Epidemiology Sante Publique, 48: 363-373.
17. Endicott, J., Nee, J., Harrison,W., Blumenthal, R. (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacological Bulletin, 29:321-326.
18. Ferri, M., Davoli, M., Perucci, C. A. (2003). Heroin maintenance for chronic heroin dependents. Cochrane Database System Review, 18:CD003410.
19. Ferri, M., Davoli, M., Peruccu, C. A. (2006). Heroin maintenance treatment for chronic heroindependent individuals: A Cochrane systematic review of effectiveness. Journal of Substance Abuse Treatment, 30:63-72.
20. Fhima, A., Henrion, R., Lowenstein, W., Charpak, Y. (2001). Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Annales de Medicine Interne, 152(Suppl. 3):IS26-IS36.
21. Fischer, G., Gombas, W., Eder, H., Jagsch, R., Peternell, A., Stuhlinger, G., et al. (1999). Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 94:1337-1347. (Pubitemid 29433792)
22. Fischer, G.,Ortner, R., Rohrmeister, K., Jagsch, R., Baewert, A., Langer, M., et al. (2006).Methadone versus buprenorphine in pregnant addicts: A double-blind, double-dummy comparison study. Addiction, 101;275-281.
23. Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., et al. (2004). Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence, 75:37-45.
24. Ghodse, A. H., Reynolds,M., Baldacchino, A. M., Dunmore, E., Byrne, S., Oyefeso, A., et al. (2002). Treating an opiate-dependent opiate-dependent inpatient population: A one-year follow-up study of treatment completers and noncompleters. Addictive Behaviors, 27:765-778.
25. Giacomuzzi, S. M., Ertl, M., Kemmler, G., Riemer, Y., Vigl, A. (2005). Sublingual buprenorphine and methadone maintenance treatment: A three-year follow-up of quality of life assessment. Scientific World Journal, 5:452-468.
26. Giacomuzzi, S. M., Riemer, Y., Ertl, M., Kemmler, G., Rossler, H., Hinterhuber, H., et al. (2003). Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health-related quality of life assessment. Addiction, 98:693-702.
27. Gibson, A. E., Doran, C.M., Bell, J. R., Ryan, A., Lintzeris, N. (2003).Acomparison of buprenorphine treatment in clinic and primary care settings: A randomised trial. Medicine Journal of Australia, 179:38-42.
28. Goldberg, D. P., Williams, P. A. (1988). Users guide to the General Health Questionnaire: GHQ. Windsor, UK: NFER-NELSON.
29. Gossop, M., Marsden, J., Stewart, D., Kidd, T. (2003). The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction, 98:291-303.
30. Gossop, M., Marsden, J., Stewart, D., Rolfe, A. (1999). Treatment retention and 1 year outcomes for residential programmes in England. Drug and Alcohol Dependence, 57:89-98.
31. Guy, W. (1976). ECDEU assessment manual for psychopathology. U.S. Department of Health, Education and Welfare Publication (ADM) 76-388 (pp. 218-222, 534-537). Rockville, MD: National Institute of Mental Health.
32. Ho, B. C., Nopoulos, P., Flaum, M., Arndt, S., Andreasen, N. C. (1998). Two-year outcome in firstepisode schizophrenia: Predictive value of symptoms for quality of life. American Journal of Psychiatry, 155:1196-1201.
33. Hubbard, R. L., Craddock, S. G., Flynn, P. M., Anderson, J., Etheridge, R. M. (1997). Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors, 11:261-278. (Pubitemid 28046589)
34. Jasinski, D. R., Pevnick, J. S., Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Archives of General Psychiatry, 35:501-516.
35. Johnson, R. E., Jaffe, J. N., Fudala, P. J. (1992). A controlled trial of buprenorphene treatment for opioid dependence. Journal of American Medical Asociation, 267:2750-2755.
36. Kakko, J., Svanborg, K. D., Kreek, M. J., Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet, 361:662-668.
37. Koivumaa-Honkanen, H. T., Honkanen, R., Antikainen, R., Hintikka, J., Viinamaki, H. (1999). Selfreported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder. Acta Psychiatrica Scandinavica, 99:377-384.
38. Kosten, T. R., George, T. P. (2002). The neurobiology of opioid dependence: Implications for treatment. Science & Practice Perspectives, 13:13-20.
39. Kosten, T. R., Schottenfeld, R., Ziedonis, D., Falcioni, J. (1993). Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease, 181:358-364. (Pubitemid 24259606)
40. Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Jr., Kintaudi, P., et al. (1998). Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction, 93:475-486.
41. Ling,W.,Wesson, D. R., Charuvastra, C., Klett, C. J. (1996). A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry, 53:401-407.
42. Macdonald, E. M., Pica, S., Mcdonald, S., Hayes, R. L., Baglioni, A. J., Jr. (1998). Stress and coping in early psychosis. Role of symptoms, self-efficacy, and social support in coping with stress. British Journal of Psychiatry, 172(Suppl. 33):122-127.
43. Marsch, L. A., Stephens,M. A., Mudric, T., Strain, E. C., Bigelow, G. E., Johnson, R. E. (2005). Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental Clinical Psychopharmacology, 13:293-302.
44. Mattick, R. P., Breen, C., Kimber, J., Davoli, M. (2003). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Review, The Cochrane Library, Issue 3, Oxford, Software update.
45. Mattick, R. P., Kimber, J., Breen, C., Davoli, M. (2003). Buprenorphine maintenance versus placebo or methadone maintenance for opioid deprendence. Cochrane Review. The Cochrane Library, Issue 3, Oxford, Software update.
46. McDowell, D. M., Cocke, C. (2006). Office-based treatment of opiate-dependent patients with buprenorphine: Its about time. Primary Psychiatry, 13:68-73.
47. Metzger, D. S., Navaline, H.,Woody, G. E. (1998). Drug abuse treatment as AIDS prevention. Public Health Reports, 113(Suppl. 1):97-106.
48. Middel, B., Stewart, R., Bouma, J., et al. (2001).Howto validate clinically important change in healthrelated functional status. Is the magnitude of the effect size consistently related to magnitude of change as indicated by a global question rating? Journal of Evaluation in Clinical Practice, 7:399-410.
49. Montoya, I. D., Schroeder, J. R., Preston, K. L., Covi, L., Umbricht, A., Contoreggi, C., et al. (2005). Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment, 28:247-254.
50. Nestler, E. J. (1997). Basic neurobiology of opiate addiction. In S. M. Stine & T. R. Kosten (Eds.), New treatments for opiate dependence (p. 286). New York: Guilford Press.
51. Nestler, E. J., Aghajanian, G. K. (1997). Molecular and cellular basis of addiction. Science, 278: 58-63.
52. Nigam, A. K., Ray, R., Tripathi, B. M. (1993). Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment, 10:391-394.
53. O'Connor, P. G., Fiellin, D. A. (2000). Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine, 133:40-54.
54. O'Connor, P.G., Oliveto, A. H., Shi, J.M., Triffleman, E. G.,Carroll, K. M.,Kosten, T. R., et al. (1998). A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine, 105:100-105.
55. Ponizovsky, A. M., Grinshpoon, A., Margolis, A., Cohen, R., Rosca, P. (2006). Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine. Addictive Behaviors, 31:2002-2013.
56. Ponizovsky,A., Grinshpoon, A., Sasson, R., Levav, I. (2004). Stress in adult studentswith schizophrenia in a supported education program. Comprehensive Psychiatry, 45:401-407.
57. Ritsner, M.,Modai, I., Endicott, J., Rivkin, O., Nechamkin, Y., Barak, P., et al. (2000). Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry, 61:880-889.
58. Ritsner, M., Ponizovsky, A., Endicott, J., Nechamkin, Y., Rauchverger, B., Silver, H., et al. (2002). The impact of adverse events of antipsychotics on life satisfaction of schizophrenia patients: A naturalistic study. European Neuropsychopharmacology, 12:31-38.
59. Schottenfeld, R. S., Pakes, J. R., Kosten, T. R. (1998). Prognostic factors in buprenorphine- versus methadone-maintained patients. Journal of Nervous and Mental Disease, 186:35-43.
60. Schwarzer, R., Jerusalem, M. (1995). Generalized Self-Efficacy scale. In J. Weinman, S. Wright, & M. Johnston, (Eds.), (Measures in health psychology: A user's portfolio. Causal and control beliefs (pp. 35-37). Windsor, UK: NFER-NELSON.
61. Sees, K. L., Delucchi, K. L, Masson, C., Rosen, A., Clark, H. W. (2000). Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trail. Journal of American Medical Association, 283:303-1310.
62. Seifert, J.,Metzner, C., Paetzold,W., Borsutzky, M., Ohlmeier, M., Passie, T., et al. (2005).Mood and affect during detoxification of opiate addicts: A comparison of buprenorphine versus methadone. Addiction Biology, 10:157-164.
63. Shaham, Y., Erb, S., Stewart, J. (2000). Stress-induced relapse to heroin and cocaine seeking in rats: A review. Brain Research Reviews, 33:13-33. (Pubitemid 30680026)
64. Simoens, S., Matheson, C., Bond, C., Inkster, K., Ludbrook, A. (2005). The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. British Journal of General Practice, 55:139-146.
65. Smyth, B. P., Barry, J., Lane, A., Cotter, M., O'Neill, M., Quinn, C., et al. (2005). In-patient treatment of opiate dependence: Medium-term follow-up outcomes. British Journal of Psychiatry, 187:360-365.
66. Soyka,M., Penning, R.,Wittchen, U. (2006). Fatal poisoning in methadone and buprenorphine treated patients-are there differences? Pharmacopsychiatry, 39:85-87.
67. Stein, M. D., Cioe, P., Friedmann, P. D. (2005). Buprenorphine retention in primary care. Journal of General Internal Medicine, 20:1038-1041.
68. Strain, E. C., Stitzer, M. L., Liebson, I. A., Bigelow, G. E. (1994). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry, 151:1025-1030.
69. Strain, E. C., Stitzer, M. L., Liebson, I. A., Bigelow, G. E. (2002). Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. Journal of Clinical Psychopharmacology, 16:58-67.
70. Sullivan, L. E., Chawarski, M., O'Connor, P. G., Schottenfeld, R. S., Fiellin, D. A. (2005). The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug and Alcohol Dependence, 79:113-116.
71. Testa, M. A., Simonson, D. C. (1996). Assessment of quality of life outcomes. New England Journal of Medicine, 334:835-840.
72. Torrens, M., Domingo-Salvany, A., Alonso, J., Castillo, C., San, L. (1999). Methadone and quality of life. Lancet, 353:1101.
73. Torrens, M., San, L., Martinez, A., Castillo, C., Domingo-Salvany, A., Alonso, J. (1997). Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction, 92:707-716.
74. Turner, R. J., Marino, F. (1994). Social support and social structure: A descriptive epidemiology. Journal of Health and Social Behavior, 35:193-212.
75. van de Velde, J. C., Schaap, G. E., Land, H. (1998). Follow-up at a Dutch addiction hospital and the effectiveness of therapeutic community treatment. Substance Use and Misuse, 33:1611-1627.
76. Walsh, S. L., June, H. L., Schuh, K. J., Preston, K. L., Bigelow, G. E., Stitzer, M. L. (1995). Effects of buprenorphine andmethadone in methadone-maintained subjects. Psychopharmacology, 119:268-276.
77. Wilson, I. B., Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. Journal of American Medical Association, 273:59-65.
78. Zimet, G. D., Dahlem, N. W., Zimet, S. G., Farley, G. K. (1988). The Multidimensional Scale of Perceived Social Support. Journal of Personality Assessment, 52:30-41.